Healthcare
Hikma Pharmaceuticals PLC(HKMPY)
Live Price
Offline$39.05
-0.13% today
1Y Change
-30.52%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $4.09B
- Revenue Growth
- +7.3%
- EPS Growth
- +13.0%
- Dividend Yield
- 4.4%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hikma Pharmaceuticals PLC (HKMPY) is a Healthcare stock with a market cap of $4.09B and listed on OTC. The stock last traded around $39.05 and down 30.5% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +7.3%, EPS growth of +13.0%, a dividend yield of 4.4%. What stands out right now is revenue +7.3%, EPS +13.0%, free cash flow -50.6% with operating margin 16.8% and ROIC 10.2%. The dividend matters to the case here, with a current yield around 4.4%. Valuation is more restrained than many high-expectation growth names at P/E 10.4 and price/sales 1.2. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines HKMPY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.3% vs +7.6% peer median
Operating Margin
Below sector median
+16.8% vs +19.4% peer median
P/E
Below sector median
10.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 24, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +7.3% and EPS at +13.0%, with operating margin around 16.8%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 24, 2026 | โ | +1.0% | -25.8% | -25.9% |
2025 Aug 7, 2025 | โ | +1.5% | +1.5% | -1.3% |
2025 Feb 26, 2025 | โ | +0.0% | -1.6% | -2.1% |
Benchmark Edge
HKMPY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HKMPY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HKMPY Max Drawdown
-43.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HKMPY and SPY.
Company Overview
Hikma Pharmaceuticals PLC
Other OTC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
- Leadership
- Said Samih Taleb Darwazah
- IPO Date
- Feb 7, 2012
- Employees
- 9.5k
- Street Address
- 1 New Burlington Place
- Mailing
- London, W1S 2HR
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 7399 2760
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 10.4
- EV/EBITDA
- 8.1
- Price/Sales
- 1.2
- Price/Book
- 1.6
Growth
- Revenue
- +7.3%
- EPS
- +13.0%
- Free Cash Flow
- -50.6%
Profitability
- Gross Margin
- 41.4%
- Operating Margin
- 16.8%
- Net Margin
- 12.0%
- ROE
- 15.8%
- ROIC
- 10.2%
Balance Sheet
- Debt/Equity
- 0.64
- Current Ratio
- 1.82
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.